CAS: 2127-09-5; 5-Nitropyridine-2(1H)-Thione

相似化合物

38240-21-0 27885-56-9 1516841-23-8

上下游产品

CAS号4487-59-6 2-溴-5-硝基吡啶 | CAS号67-56-1 甲醇 | CAS号650608-81-4 5-nitropyrid-2-... | CAS号64-17-5 乙醇 | CAS号2127-10-8 2,2'-二硫双(5-硝基吡啶) | CAS号4548-45-2 2-氯-5-硝基吡啶 | CAS号1309779-40-5 5-nitro-2-pyrid... | CAS号107756-05-8 2-乙硫基-5-硝基吡啶 | CAS号465529-94-6 5-硝基吡啶-2-磺酸 | CAS号4214-76-0 2-氨基-5-硝基吡啶 | CAS号20885-21-6 5-硝基-2-甲基硫代吡啶 | CAS号27885-56-9 3-氨基-6-疏基吡啶 | CAS号27885-57-0 N-(6-sulfanylid... | CAS号64356-57-6 5-氨基-2-吡啶磺酰胺 | CAS号2127-10-8 2,2'-二硫双(5-硝基吡啶) | CAS号75903-49-0 5-nitropyridine... | CAS号174485-82-6 5-硝基吡啶-2-磺酰氯

📜2-羟基-5-硝基吡啶置于劳森试剂体系中,用 2-甲基-2-丁醇 用作溶剂,化学反应生成2-巯基-5-硝基吡啶
参考文献:If 5影响cl-F交换氟化的最后阶段中的五氟-λ合成6硫烷基-吡啶,嘧啶和苯与吸电子取代基
标题:If 5影响cl-F交换氟化的最后阶段中的五氟-λ合成6硫烷基-吡啶,嘧啶和苯与吸电子取代基
摘要:在五氟λ的制备的最后阶段甲难以氯-氟(cl-F)交换氟化反应6具有吸电子取代基-Sulfanyl-(杂)芳烃现已通过使用五氟化碘的阐明.F和i与卤素键之间的潜在相互作用充分抑制了cs键断裂的主要副反应.
Doi:10.1039/c7Cc02802D

专利信息

专利号:US-2023220001-A1
优先权日:2020-06-09
标 题:Method for synthesis of thioether-containing peptides
发明人：GRUSS HENDRIK; LUTZ CHRISTIAN; SÃœSSMUTH RODERICH; Yao guiyang; KNITTEL CAROLINE; KOSOL SIMONE; MAINZ ANDI
权利人:HEIDELBERG PHARMA RES GMBH
摘要:The present invention relates to a method of formation of a sulphur bridge between tryptophan and cysteine in solid phase peptide synthesis under iodine treatment. The invention also relates to the resulting compounds of the method and their respective use.

专利号:US-7456309-B2
优先权日:2004-12-16
标 题:Reusable universal polymer support for repetitive oligonucleotide synthesis
发明人：KUMAR PRADEEP; GUPTA KAILASH CHAND
权利人:COUNCIL SCIENT IND RES
摘要:The present invention provides a reusable, universal polymer support for repetitive oligonucleotide synthesis and a method of synthesis thereof.

专利号:US-4171438-A
优先权日:1975-07-23
标 题:0-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents
发明人：DOUGLAS JAMES L; HORNING DONALD E; MORRIS LEESON R
权利人:BRISTOL MYERS CO
摘要:There is described the stereoselective total synthesis of novel DELTA 2,3-1,4-morpholine-2-carboxylic acids possessing a fused beta -lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula I wherein X is acylamino and Z represents optionally substituted C1-C6 alkyl, aryl or aralkyl. Also included in the invention are compounds of the above formula in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds. The compounds are potent antibacterial agents.

专利号:US-4118566-A
优先权日:1975-07-23
标 题:Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents
发明人：HORNING DONALD E; MORRIS LEESON R; DOUGLAS JAMES L
权利人:BRISTOL MYERS CO
摘要:There is described the stereoselective total synthesis of novel DELTA 2,3-1,4-morpholine-2-carboxylic acids possessing a fused beta -lactam ring in the 1,6-position and carrying a substituent cis to carbon 5 in the 7-position of the fused ring system represented by the general formula I wherein X is amino, azido or acylamido and Z represents optionally substituted C1-C6 alkyl, aryl, aralkyl or heterocyclic. Also included in the invention are compounds of formula I in which the carboxyl group at the 2-position is protected as by an easily cleavable ester group and salts of both the free acids and carboxyl-protected compounds of formula I. The compounds of formula I are potent antibacterial agents or are of use as intermediates in the preparation of such antibacterial agents.

专利号:WO-2021250059-A1
优先权日:2020-06-09
标题 :Method for synthesis of thioether-containing peptides

专利号:US-12403201-B2
优先权日:2021-03-19
标题:B-lymphocyte specific amatoxin antibody conjugates
发明人：HECHLER TORSTEN; KULKE MICHAEL; PAHL ANDREAS
权利人:HEIDELBERG PHARMA RES GMBH
摘要:The present application relates to conjugates comprising an amatoxin a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell-, particularly B-cell and/or lymphoma associated diseases and/or malignancies.